Esperion Therapeutics (ESPR) Return on Capital Employed: 2019-2025
Historic Return on Capital Employed for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to 8.44%.
- Esperion Therapeutics' Return on Capital Employed rose 834.00% to 8.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.44%, marking a year-over-year increase of 834.00%. This contributed to the annual value of 1.90% for FY2024, which is 411.00% up from last year.
- As of Q3 2025, Esperion Therapeutics' Return on Capital Employed stood at 8.44%, which was up 975.42% from -0.96% recorded in Q2 2025.
- Esperion Therapeutics' Return on Capital Employed's 5-year high stood at 8.44% during Q3 2025, with a 5-year trough of -2.71% in Q4 2023.
- In the last 3 years, Esperion Therapeutics' Return on Capital Employed had a median value of -0.63% in 2025 and averaged 0.04%.
- Per our database at Business Quant, Esperion Therapeutics' Return on Capital Employed slumped by 176bps in 2023 and then surged by 834bps in 2025.
- Esperion Therapeutics' Return on Capital Employed (Quarterly) stood at -0.99% in 2021, then grew by 3bps to -0.95% in 2022, then plummeted by 176bps to -2.71% in 2023, then soared by 337bps to 0.66% in 2024, then skyrocketed by 834bps to 8.44% in 2025.
- Its Return on Capital Employed stands at 8.44% for Q3 2025, versus -0.96% for Q2 2025 and -0.63% for Q1 2025.